HBM Partners backs APR

APR had already received investment from the Bright Technology Fund (BTF). Together, HBM BioCapital II Management and BTF hold a 56% stake in the company, while APR's founders hold a 36% stake. The management team holds a 1% stake in the company.

Company
APR develops over-the-counter healthcare products covering the prescription and consumer markets. It focuses in particular on oncology, wound management, pain management, dermatology, gynaecology and pregnancy. The compnay has licensing and partnership agreements with pharmaceutical companies in 70 countries worldwide. Founded in 2014, APR is headquartered in Balerna.

People
Alexander Asam is an adviser to HBM and will take a seat on the APR board. Paolo Galfetti is CEO and co-founder of APR. Valentina Reiner is co-founder of APR and retains a management role as part of the transaction, but will no longer sit on the company's board.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Expansion
• Healthcare
• Switzerland